StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.DE cash

Cash and short-term investments held at the end of each period.

Viridian Therapeutics, Inc.DE's cash was $981.50M at Jun 30, 2026. For fiscal 2025 it was $874.70M, up 21.9% from the year before. Over ten years it grew 45.0% a year on average. The highest annual figure on record is $874.70M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$874.70M+21.9%
FY2024Dec 31, 2024$717.60M+50.3%
FY2023Dec 31, 2023$477.40M+12.4%
FY2022Dec 31, 2022$424.60M+115.5%
FY2021Dec 31, 2021$197.00M+54.4%
FY2020Dec 31, 2020$127.60M+376.1%
FY2019Dec 31, 2019$26.80M-57.1%
FY2018Dec 31, 2018$62.48M+31.7%
FY2017Dec 31, 2017$47.44M+114.6%
FY2016Dec 31, 2016$22.10M+4.1%
FY2015Dec 31, 2015$21.24M+314.8%
FY2014Dec 31, 2014$5.12M+2349.3%
FY2013Dec 31, 2013$209.00K+86.6%
FY2012Dec 31, 2012$112.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$981.50M+74.2%
Q1 FY2026Mar 31, 2026$762.20M+19.7%
Q4 FY2025Dec 31, 2025$874.70M+21.9%
Q3 FY2025Sep 30, 2025$490.90M-34.8%
Q2 FY2025Jun 30, 2025$563.40M-1.4%
Q1 FY2025Mar 31, 2025$636.60M+3.8%
Q4 FY2024Dec 31, 2024$717.60M+50.3%
Q3 FY2024Sep 30, 2024$753.20M+140.6%
Q2 FY2024Jun 30, 2024$571.40M+70.9%
Q1 FY2024Mar 31, 2024$613.20M+64.0%
Q4 FY2023Dec 31, 2023$477.40M+12.4%
Q3 FY2023Sep 30, 2023$313.00M-27.4%
Q2 FY2023Jun 30, 2023$334.30M+107.4%
Q1 FY2023Mar 31, 2023$373.90M+113.2%
Q4 FY2022Dec 31, 2022$424.60M+115.5%
Q3 FY2022Sep 30, 2022$431.30M+101.7%
Q2 FY2022Jun 30, 2022$161.20M+47.5%
Q1 FY2022Mar 31, 2022$175.40M+49.8%
Q4 FY2021Dec 31, 2021$197.00M+54.4%
Q3 FY2021Sep 30, 2021$213.80M+610.8%
Q2 FY2021Jun 30, 2021$109.30M+257.2%
Q1 FY2021Mar 31, 2021$117.10M+224.4%
Q4 FY2020Dec 31, 2020$127.60M+376.1%
Q3 FY2020Sep 30, 2020$30.08M-11.0%
Q2 FY2020Jun 30, 2020$30.60M-30.3%
Q1 FY2020Mar 31, 2020$36.10M-29.2%
Q4 FY2019Dec 31, 2019$26.80M-57.1%
Q3 FY2019Sep 30, 2019$33.80M-52.1%
Q2 FY2019Jun 30, 2019$43.90M-42.4%
Q1 FY2019Mar 31, 2019$51.00M-34.7%
Q4 FY2018Dec 31, 2018$62.48M+31.7%
Q3 FY2018Sep 30, 2018$70.53M+64.8%
Q2 FY2018Jun 30, 2018$76.26M+64.6%
Q1 FY2018Mar 31, 2018$78.10M+68.6%
Q4 FY2017Dec 31, 2017$47.44M+114.6%
Q3 FY2017Sep 30, 2017$42.81M+74.0%
Q2 FY2017Jun 30, 2017$46.34M–
Q1 FY2017Mar 31, 2017$46.34M–
Q4 FY2016Dec 31, 2016$22.10M–
Q3 FY2016Sep 30, 2016$24.60M–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?